Exagen (XGN) AI Stock Analysis

• Market Cap: $202.43M
• Dividend Yield: N/A
• Average Volume (3M): 345.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: 3.89%
• EPS Growth: 7.92%
• Country: US
• Employees: 209
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.21
• Shares Outstanding: 22,003,641
• 10 Day Avg. Volume: 511,103
• 30 Day Avg. Volume: 345,867
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: 2.42
• Enterprise Value/Gross Profit: 4.07
• Enterprise Value/Ebitda: -11.66
• 1Y Price Target: $10.86
• Price Target Upside: 15.78% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 61 Neutral
• Price Target: $9.00 ▼(-4.05% Downside)

Exagen's overall stock score reflects a mix of strong technical momentum and positive corporate developments, balanced by significant financial challenges and valuation concerns. The stock shows promise with strategic advancements and growth in key metrics, yet profitability issues and a negative P/E ratio are notable risks.

Positive Factors

Earnings

XGN delivered a 5% revenue beat in Q2 and grew the top line by 14% driven by balanced growth from volume and pricing gains.

Financial Performance

Exagen's efforts in recent years to increase ASP are paying dividends.

Product Launch

XGN is feeling good about its new biomarker launches and is optimistic that its new biomarkers can pull forward even higher ASPs.

Negative Factors

Cash Flow

The focus on cutting the cash burn via narrowing the commercial efforts to focus on profitable accounts is paying off.

Debt Management

Exagen's new credit facility enabled it to refinance its debt and provides additional capital for future needs.

Market Penetration

With <10% market penetration and an expanding sales force, management sounds confident that this volume growth is sustainable.

Exagen Business Overview & Revenue Model

Company Description

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

How the Company Makes Money

Exagen generates revenue primarily through the sale of its diagnostic tests to healthcare providers and laboratories. The company operates on a fee-for-service model, where it charges for each test performed. Key revenue streams include direct sales of AVISE® tests to clinicians, reimbursement from insurance companies for tests provided to patients, and collaborations with pharmaceutical companies for companion diagnostics. Additionally, Exagen may benefit from partnerships with healthcare organizations that enhance its market reach and credibility, contributing to its overall earnings potential.

Exagen Financial Statement Overview

Summary

Exagen's revenue growth is positive, yet financial health is challenged by persistent losses, high leverage, and negative cash flow. The robust gross margin is overshadowed by declining equity and high liabilities.

Income Statement

Exagen's revenue growth has been positive, with a 2% increase from the previous annual report to the TTM (Trailing-Twelve-Months). However, the company is struggling with profitability as evidenced by negative EBIT and net profit margins. The gross profit margin is healthy at 59.3% for the TTM, showing good control over cost of goods sold, but overall profitability remains a concern.

Balance Sheet

The balance sheet reflects a high debt-to-equity ratio of 0.79, indicating significant leverage. The equity ratio has decreased to 15.9% in the TTM, showing reduced equity as a percentage of total assets. Return on equity remains negative due to continuous net losses. The financial position is weakened by declining equity and high liabilities.

Cash Flow

Exagen's cash flow situation is challenging, with negative free cash flow and operating cash flow. The free cash flow to net income ratio is slightly negative, indicating cash flow issues relative to earnings. There is a lack of positive cash flow trends, and the company is reliant on external financing to manage its operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	55.64M	52.55M	45.56M	48.30M	41.98M
Gross Profit	33.11M	29.46M	21.35M	27.71M	25.42M
EBITDA	-11.14M	-19.15M	-43.11M	-23.10M	-13.65M
Net Income	-15.12M	-23.69M	-47.39M	-26.85M	-16.69M
Balance Sheet
Total Assets	44.69M	56.94M	86.22M	123.44M	78.38M
Cash, Cash Equivalents and Short-Term Investments	22.04M	36.49M	62.39M	99.44M	57.45M
Total Debt	23.36M	23.72M	34.50M	27.48M	26.66M
Total Liabilities	35.15M	34.25M	43.76M	38.51M	36.54M
Stockholders Equity	9.54M	22.69M	42.46M	84.94M	41.84M
Cash Flow
Free Cash Flow	-13.79M	-15.29M	-36.46M	-22.64M	-14.54M
Operating Cash Flow	-13.28M	-14.46M	-32.14M	-20.27M	-14.08M
Investing Cash Flow	-515.00K	-804.00K	-4.32M	-2.42M	-455.00K
Financing Cash Flow	-663.00K	-10.63M	-489.00K	64.68M	-97.00K

Exagen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XGN, the sentiment is Positive. The current price of 9.38 is above the 20-day moving average (MA) of 7.97, above the 50-day MA of 7.46, and above the 200-day MA of 5.07, indicating a bullish trend. The MACD of 0.58 indicates Negative momentum. The RSI at 79.44 is Negative, neither overbought nor oversold. The STOCH value of 97.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XGN.

Exagen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥339.25B	10.33	-0.16%	2.41%	10.20%	-8.92%
XGN	61 Neutral	$202.43M	―	-87.94%	―	3.89%	7.92%
MDXH	53 Neutral	$131.66M	―	-1552.23%	―	22.56%	41.55%
BNR	51 Neutral	$73.39M	―	-37.15%	―	-0.26%	60.09%
BDSX	50 Neutral	$57.23M	―	-219.68%	―	25.70%	39.23%
SERA	50 Neutral	$93.43M	―	-44.24%	―	0.93%	13.99%
VNRX	47 Neutral	$64.47M	―	138.92%	―	64.15%	41.65%

Exagen Corporate Events

Exagen Appoints Chas McKhann to Board of Directors

On July 17, 2025, Exagen Inc. announced the appointment of Chas McKhann to its Board of Directors, highlighting his extensive experience in the life sciences industry and previous leadership roles in companies acquired by Boston Scientific. This strategic move is expected to bolster Exagen’s growth and enhance its position in the autoimmune diagnostics market, aiming to drive strategic growth and create long-term value for patients, providers, and shareholders.

The most recent analyst rating on (XGN) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Exagen stock, see the XGN Stock Forecast page.

Exagen Inc. Holds 2025 Annual Stockholder Meeting

Exagen Inc. held its 2025 annual meeting of stockholders on June 10, 2025, where four proposals were voted on. The stockholders elected two Class III directors for a three-year term, ratified the appointment of BDO USA, P.C. as the independent auditor for 2025, approved executive compensation, and decided to hold annual advisory votes on executive compensation.

The most recent analyst rating on (XGN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Exagen stock, see the XGN Stock Forecast page.